Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSEMKT:IGCNASDAQ:MISTNASDAQ:TNYANYSEAMERICAN:ZOM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIGCIGC Pharma$0.30-7.7%$0.30$0.25▼$0.55$23.91M1.48338,860 shs214,616 shsMISTMilestone Pharmaceuticals$1.72-0.6%$1.36$0.63▼$2.75$91.96M0.92932,153 shs562,341 shsTNYATenaya Therapeutics$0.58+0.8%$0.49$0.36▼$4.06$94.10M2.912.62 million shs1.52 million shsZOMZomedica$0.12$0.09▼$0.17$95.35M1.034.52 million shs790,936 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIGCIGC Pharma0.00%-3.53%-1.63%-4.44%+30,099,900.00%MISTMilestone Pharmaceuticals-0.58%0.00%+33.33%-11.79%+23.74%TNYATenaya Therapeutics+0.78%-8.47%+18.06%-11.69%-81.69%ZOMZomedica0.00%0.00%0.00%0.00%-35.43%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationIGCIGC Pharma1.3792 of 5 stars3.50.00.00.00.61.70.0MISTMilestone Pharmaceuticals2.1595 of 5 stars3.23.00.00.01.82.50.0TNYATenaya Therapeutics3.3976 of 5 stars3.53.00.00.01.44.21.3ZOMZomedicaN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIGCIGC Pharma 3.00Buy$3.881,187.38% UpsideMISTMilestone Pharmaceuticals 2.40Hold$7.00306.98% UpsideTNYATenaya Therapeutics 3.00Buy$6.25980.38% UpsideZOMZomedica 4.00Strong BuyN/AN/ACurrent Analyst Ratings BreakdownLatest IGC, ZOM, TNYA, and MIST Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/5/2025MISTMilestone PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeBuy$5.005/9/2025TNYATenaya TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $9.004/25/2025TNYATenaya TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.004/1/2025MISTMilestone PharmaceuticalsCowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold4/1/2025MISTMilestone PharmaceuticalsTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold4/1/2025MISTMilestone PharmaceuticalsTD SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold3/31/2025TNYATenaya TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.003/28/2025MISTMilestone PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.00 ➝ $25.00(Data available from 6/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIGCIGC Pharma$1.24M19.41N/AN/A$0.08 per share3.76MISTMilestone Pharmaceuticals$1M91.95N/AN/A$0.25 per share6.88TNYATenaya TherapeuticsN/AN/AN/AN/A$1.07 per shareN/AZOMZomedica$25.19M0.00N/AN/A$0.24 per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIGCIGC Pharma-$13M-$0.11N/AN/AN/A-714.16%-122.44%-88.40%N/AMISTMilestone Pharmaceuticals-$41.52M-$0.78N/AN/AN/AN/A-329.85%-67.20%8/6/2025 (Estimated)TNYATenaya Therapeutics-$111.13M-$1.16N/AN/AN/AN/A-92.20%-74.53%8/14/2025 (Estimated)ZOMZomedica-$34.53M-$0.06N/AN/AN/A-232.88%-12.47%-11.84%N/ALatest IGC, ZOM, TNYA, and MIST EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025MISTMilestone Pharmaceuticals-$0.19-$0.31-$0.12-$0.31N/AN/A5/7/2025Q1 2025TNYATenaya Therapeutics-$0.18-$0.24-$0.06-$0.24N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthIGCIGC PharmaN/AN/AN/AN/AN/AMISTMilestone PharmaceuticalsN/AN/AN/AN/AN/ATNYATenaya TherapeuticsN/AN/AN/AN/AN/AZOMZomedicaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIGCIGC Pharma0.021.150.98MISTMilestone Pharmaceuticals4.064.674.67TNYATenaya TherapeuticsN/A6.686.68ZOMZomedicaN/A10.8210.15Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIGCIGC Pharma3.87%MISTMilestone Pharmaceuticals86.18%TNYATenaya Therapeutics90.54%ZOMZomedica8.95%Insider OwnershipCompanyInsider OwnershipIGCIGC Pharma31.48%MISTMilestone Pharmaceuticals19.50%TNYATenaya Therapeutics48.65%ZOMZomedica4.19%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIGCIGC Pharma6179.69 million54.60 millionN/AMISTMilestone Pharmaceuticals3053.46 million43.04 millionOptionableTNYATenaya Therapeutics110162.67 million83.53 millionOptionableZOMZomedica50979.95 million938.89 millionNot OptionableIGC, ZOM, TNYA, and MIST HeadlinesRecent News About These CompaniesZomedica Corp.: Zomedica Unveils Exclusive Fourth Friday at Four Webinar Series to Explore Cutting-Edge Veterinary InnovationsMay 20, 2025 | finanznachrichten.deTreat pet pain, inflammation, and anxiety with this high-tech at home therapyApril 24, 2025 | click2houston.comHelping Pets Live Pain-Free: High-Tech Treatments for Our Four-Legged Family MembersApril 11, 2025 | pix11.comIs Zomedica Corp. (ZOMDF) the Cheapest Stock Insiders Are Buying In March?March 28, 2025 | insidermonkey.com15 Cheapest Stocks Insiders Are Buying In MarchMarch 27, 2025 | insidermonkey.comEarnings call transcript: Zomedica Q4 2024 shows revenue growthMarch 15, 2025 | investing.comQ4 2024 Zomedica Corp Earnings CallMarch 15, 2025 | finance.yahoo.comZomedica Corp. (ZOMDF) Q4 2024 Earnings Call TranscriptMarch 13, 2025 | seekingalpha.comZomedica (ZOMDF) Gets a Buy from Noble FinancialMarch 11, 2025 | markets.businessinsider.comZomedica Corp.March 8, 2025 | wsj.comZomedica Corp. Announces Transition to OTCQB Venture MarketMarch 4, 2025 | accessnewswire.comNYSE American to Commence Delisting Proceedings Against Zomedica Corp. (ZOM)March 4, 2025 | businesswire.comZomedica to Report Fourth Quarter and Full Year 2024 Financial Results with a Business Update on March 13th at 4:30 p.m. ETFebruary 26, 2025 | accessnewswire.comZomedica Corp.: Zomedica Improves Efficiency and Cuts Costs by Moving to New HeadquartersFebruary 12, 2025 | finanznachrichten.deZomedica Improves Efficiency and Cuts Costs by Moving to New HeadquartersFebruary 12, 2025 | accessnewswire.comZomedica Corp.: Zomedica Launches the TRUFORMA Enhanced Endogenous ACTH Assay to aid in Equine PPID DiagnosisFebruary 6, 2025 | finanznachrichten.deZomedica Launches the TRUFORMA(R) Enhanced Endogenous ACTH Assay to aid in Equine PPID DiagnosisFebruary 6, 2025 | accessnewswire.comZomedica Corp (ZOM) Stock Sees Market Value Hit $118.58 million: What Are the Implications?February 4, 2025 | bovnews.comZomedica Corp (ZOM) Stock Trading RecapJanuary 17, 2025 | bovnews.comZomedica Corp (ZOM) Stock’s -0.13% Decrease This Year: What’s the Story?January 13, 2025 | bovnews.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIGC, ZOM, TNYA, and MIST Company DescriptionsIGC Pharma NYSEMKT:IGC$0.30 -0.03 (-7.70%) Closing price 06/18/2025 03:58 PM EasternExtended Trading$0.30 0.00 (-0.33%) As of 06/18/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.IGC Pharma, Inc., a clinical stage pharmaceutical company, engages in developing treatments for Alzheimer's disease. The company's lead product is IGC-AD1, which is in a Phase 2B clinical trial as a treatment for agitation in dementia due to Alzheimer's; and TGR-63, IGC-1C, IGC-M3, and LMP in pre-clinical development. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. The company was incorporated in 2005 and is headquartered in Potomac, Maryland.Milestone Pharmaceuticals NASDAQ:MIST$1.72 -0.01 (-0.58%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$1.72 0.00 (0.00%) As of 06/18/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans, as well as with the Montreal Heart Institute, the WCN network, and other research centers. The company was incorporated in 2003 and is headquartered in Montréal, Canada.Tenaya Therapeutics NASDAQ:TNYA$0.58 +0.00 (+0.78%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$0.57 0.00 (-0.61%) As of 06/18/2025 07:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage. It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.Zomedica NYSEAMERICAN:ZOMZomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company offers diagnostic products comprising TRUFORMA Bulk Acoustic Wave point of care diagnostic platform; TRUVIEW, a digital cystoscopy platform that offers automated slide preparation within the instrument; and VetGuardian, a zero-touch vital signs remote monitoring system. It also provides therapeutic products, including PulseVet electrohydraulic shockwave therapy platform; and Assisi Loop line of products, including the Assisi Loop, Assisi Loop Lounge, and DentaLoop devices that treat pain and inflammation through delivery of targeted pulsed electromagnetic field focused energy. The company has collaboration agreements with Celsee, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and Seraph Biosciences, Inc. for the development of a novel pathogen detection system. The company was formerly known as Zomedica Pharmaceuticals Corp. and changed its name to Zomedica Corp. in October 2020. Zomedica Corp. is headquartered in Ann Arbor, Michigan. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Robinhood Director Sells Millions, But HOOD Stock Eyes Gains Coinbase Stock Pops as Senate Passes GENIUS Stablecoin Bill Chime’s Smart IPO: Half the Valuation, Double the Strength 3 Tech Stocks With High and Rising Institutional Interest Salesforce Raises Prices: 3 Reasons Its Stock Price Will Follow Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
